RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	8	29	13	135	302	214
Market Cap Growth	150.17%	124.49%	-90.54%	-55.27%	41.19%	35.98%
Enterprise Value	1	24	118	188	353	192
Last Close Price	6.40	36.50	140.30	2580.00	8080.00	6070.00
PE Ratio	-	1.20	-	-	-	-
PS Ratio	1.35	4.40	0.21	1.58	4.70	34.03
PB Ratio	123.39	13.88	-0.26	15.23	21.80	3.57
P/TBV Ratio	-	-	-	-	-	4.97
EV/Sales Ratio	0.40	3.67	1.92	2.19	5.49	30.58
Debt / Equity Ratio	9.15	0.57	-2.53	9.89	6.27	0.06
Asset Turnover	0.13	0.07	0.36	0.47	0.51	0.09
Inventory Turnover	0.56	0.45	2.58	4.63	8.78	1.70
Quick Ratio	0.39	0.46	0.28	0.87	0.81	4.66
Current Ratio	0.74	0.84	0.44	1.09	0.96	5.01
Return on Equity (ROE)	-1708.61%	-	-	-859.70%	-206.25%	-76.09%
Return on Assets (ROA)	-44.88%	-15.71%	-15.75%	-28.06%	-31.30%	-39.56%
Return on Capital (ROIC)	-401.79%	-36.87%	-31.32%	-51.36%	-48.37%	-46.96%
Earnings Yield	-368.18%	83.26%	-560.09%	-72.30%	-25.20%	-19.76%
FCF Yield	-295.71%	-124.74%	-229.63%	-48.20%	-16.21%	-19.11%
Buyback Yield / Dilution	-697.64%	-320.45%	-32.46%	-27.72%	-22.69%	-28.43%
Total Shareholder Return	-697.64%	-320.45%	-32.46%	-27.72%	-22.69%	-28.43%

Source: S&P Capital IQ. Standard template. Financial Sources.